Key facts
- This page summarizes Mitchell E. Levinson's Form 4 filing for Pulse Biosciences, Inc. (PLSE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Nov 2023, 17:34.
Mitchell E. Levinson - 01 Nov 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)
- Reporting relationship
- Chief Strategy Officer
- Issuer ticker
- PLSE
- Reported as of
- 01 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2023, 17:34:44 UTC
- Prior SEC filing
- 14 Jul 2023
- Next SEC filing
- 17 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth B. Stratton, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mitchell E. Levinson filed Form 4 for Pulse Biosciences, Inc. (PLSE) on 03 Nov 2023.
Change
- Previous filing in this sequence was filed on 14 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 01 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $4.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.